Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
6.34(c) 6.36(c) 6.23(c) 6.23(c) 6.29(c) Last
55 685 45 689 43 649 56 859 68 770 Volume
+2.92% +0.32% -2.04% 0.00% +0.96% Change
More quotes
Financials
Sales 2020 14,7 M 17,4 M 17,4 M
Net income 2020 -28,0 M -33,2 M -33,2 M
Net cash position 2020 21,6 M 25,6 M 25,6 M
P/E ratio 2020 -6,03x
Yield 2020 -
Sales 2021 53,5 M 63,5 M 63,5 M
Net income 2021 1,70 M 2,02 M 2,02 M
Net cash position 2021 38,6 M 45,7 M 45,7 M
P/E ratio 2021 -93,2x
Yield 2021 -
Capitalization 179 M 212 M 212 M
EV / Sales 2020 10,7x
EV / Sales 2021 2,62x
Nbr of Employees 51
Free-Float 75,3%
More Financials
Company
Poxel is a biopharmaceutical company that specializes in the development of medicines for the treatment of metabolic diseases, primarily type II diabetes. At the end of 2019, the group had a portfolio of 3 products in clinical development, including 1 in Phase III (Imeglimin for the treatment of type II diabetes and its associated pathologies) and 3 in phase II (PXL770, PXL065 and PXL007 for the treatment of... 
More about the company
Notations Surperformance© of Poxel
Trading Rating : Investor Rating :
More Ratings
All news about POXEL
10/21Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Qu..
AQ
10/20POXEL : Corporate Presentation - English
PU
10/20POXEL : Provides Corporate Update and Reports Cash and Revenue for the Third Qua..
BU
10/16Poxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the Frenc..
AQ
10/15POXEL : Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the French..
BU
10/11POXEL : Corporate Presentation - English
PU
10/07POXEL : Corporate Presentation - English
PU
10/02POXEL : Announces Positive Results from Phase 2a NASH Trial with PXL770, an Oral..
AQ
10/01POXEL : Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral..
BU
09/25Poxel Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-..
AQ
09/24POXEL : Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-R..
BU
09/22Poxel Announces Participation at Upcoming Scientific and Investor Conferences
AQ
09/22POXEL : 2020 Half Year Financial Report
PU
09/21POXEL : Corporate Presentation - English
PU
09/21POXEL : Announces Participation at Upcoming Scientific and Investor Conferences
BU
More news
News in other languages on POXEL
10/21Déjà pliée, cette élection ?
10/21EN DIRECT DES MARCHES : Vivendi, Vinci, Nestlé, Iberdrola, Ericsson, Netflix, Sn..
10/20POXEL : dresse un bilan de ses activités et publie sa position de trésorerie et ..
10/20POXEL : dresse un bilan de ses activités et publie sa position de trésorerie et ..
10/16Les valeurs à suivre aujourd'hui à la Bourse de Paris Vendredi 16 octobre 202..
More news
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 18,55 €
Last Close Price 6,29 €
Spread / Highest target 234%
Spread / Average Target 195%
Spread / Lowest Target 162%
EPS Revisions
Managers
NameTitle
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Sebastien Bolze Chief Operating Officer & Executive Vice President
Anne Renevot Chief Financial Officer & Executive Vice President
Sophie Hallakou-Bozec Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
POXEL-48.44%212
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.58.33%37 775
BEIGENE, LTD.80.38%27 097